Screener
Rigel Pharmaceuticals RIGL EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Rigel Pharmaceuticals’s reported figures.
Based on trailing twelve months.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026. Open the filing →
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
FAQ
- What is Rigel Pharmaceuticals's EBITDA margin?
- Rigel Pharmaceuticals (RIGL) reported EBITDA margin of 42.4% in Q1 2026.
- How has Rigel Pharmaceuticals's EBITDA margin changed year-over-year?
- Rigel Pharmaceuticals's EBITDA margin increased by 85.5% year-over-year, from 22.8% to 42.4%.
- What is the long-term trend for Rigel Pharmaceuticals's EBITDA margin?
- Over 5 years (2020 to 2025), Rigel Pharmaceuticals's EBITDA margin has grown at a 10.8% compound annual growth rate (CAGR), from -26% to 43.5%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Rigel Pharmaceuticals's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude